Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft

Howard R. Hubbell, Hugo E Vargas, Karen L. Tsujimoto, George D. Gibson, Edward C. Pequignot, Robert D. Bigler, William A. Carter, David R. Strayer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The antitumor effects of recombinant interleukin-2 (rIL-2) and mismatched double-stranded RNA (dsRNA) were assessed in tissue culture and in a nude mouse model. Mismatched dsRNA did not show a direct antiproliferative effect against the human malignant melanoma cell line, BRO, in tissue culture. However, treatment of the BRO cells with up to 1000 units/ml rIL-2 in culture showed a slight increase in growth rate. Combined rIL-2/mismatched dsRNA treatment also demonstrated a similar slight enhancement of growth. Nude mice bearing subcutaneous tumors were treated by intraperitoneal injection of low doses (5000-20 000 units) of rIL-2 and mismatched dsRNA (500 μg). The in vivo tumor growth was significantly inhibited by the combined treatments (P <0.05) and survival was significantly increased (P <0.05). Measurement of cytotoxicity using splenocytes from treated animals showed significant augmentation of lytic activity against natural killer(NK)-sensitive YAC-1 cells in all rIL-2/mismatched dsRNA treatment groups, compared to the individual treatments or controls (P <0.05). Cytotoxicity of the splenocytes against the NK-resistant BRO cells was also augmented in animals treated with mismatched dsRNA and the highest rIL-2 dose utilized here (P <0.01). Renal, liver, and hematological toxicity was evaluated by measurement of blood urea nitrogen, creatinine, serum asparrtate aminotransferase, and a complete blood count with differential. There were no significant differences in these parameters in any of the treatment groups. Similarly, no differences in weight of the animals was seen in any treatment group. These results indicate that the combination of low-dose rIL-2 and mismatched dsRNA can potentiate host-mediated antitumor effects, yielding increased survival, without significant toxicity.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalCancer Immunology Immunotherapy
Volume35
Issue number3
DOIs
StatePublished - May 1992
Externally publishedYes

Fingerprint

Heterografts
Interleukin-2
Melanoma
Nude Mice
Therapeutics
Growth
Blood Cell Count
Blood Urea Nitrogen
Transaminases
poly(I).poly(c12,U)
Intraperitoneal Injections
Creatinine
Neoplasms
Kidney
Weights and Measures
Cell Line
Survival
Liver
Serum

Keywords

  • Antitumor effects
  • Human melanoma xenografts
  • Interleukin-2
  • Lymphokine-activated killer cells
  • Mismatched dsRNA

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft. / Hubbell, Howard R.; Vargas, Hugo E; Tsujimoto, Karen L.; Gibson, George D.; Pequignot, Edward C.; Bigler, Robert D.; Carter, William A.; Strayer, David R.

In: Cancer Immunology Immunotherapy, Vol. 35, No. 3, 05.1992, p. 151-157.

Research output: Contribution to journalArticle

Hubbell, Howard R. ; Vargas, Hugo E ; Tsujimoto, Karen L. ; Gibson, George D. ; Pequignot, Edward C. ; Bigler, Robert D. ; Carter, William A. ; Strayer, David R. / Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft. In: Cancer Immunology Immunotherapy. 1992 ; Vol. 35, No. 3. pp. 151-157.
@article{8a593f7c7fdf41f0bf0a3dac90650429,
title = "Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft",
abstract = "The antitumor effects of recombinant interleukin-2 (rIL-2) and mismatched double-stranded RNA (dsRNA) were assessed in tissue culture and in a nude mouse model. Mismatched dsRNA did not show a direct antiproliferative effect against the human malignant melanoma cell line, BRO, in tissue culture. However, treatment of the BRO cells with up to 1000 units/ml rIL-2 in culture showed a slight increase in growth rate. Combined rIL-2/mismatched dsRNA treatment also demonstrated a similar slight enhancement of growth. Nude mice bearing subcutaneous tumors were treated by intraperitoneal injection of low doses (5000-20 000 units) of rIL-2 and mismatched dsRNA (500 μg). The in vivo tumor growth was significantly inhibited by the combined treatments (P <0.05) and survival was significantly increased (P <0.05). Measurement of cytotoxicity using splenocytes from treated animals showed significant augmentation of lytic activity against natural killer(NK)-sensitive YAC-1 cells in all rIL-2/mismatched dsRNA treatment groups, compared to the individual treatments or controls (P <0.05). Cytotoxicity of the splenocytes against the NK-resistant BRO cells was also augmented in animals treated with mismatched dsRNA and the highest rIL-2 dose utilized here (P <0.01). Renal, liver, and hematological toxicity was evaluated by measurement of blood urea nitrogen, creatinine, serum asparrtate aminotransferase, and a complete blood count with differential. There were no significant differences in these parameters in any of the treatment groups. Similarly, no differences in weight of the animals was seen in any treatment group. These results indicate that the combination of low-dose rIL-2 and mismatched dsRNA can potentiate host-mediated antitumor effects, yielding increased survival, without significant toxicity.",
keywords = "Antitumor effects, Human melanoma xenografts, Interleukin-2, Lymphokine-activated killer cells, Mismatched dsRNA",
author = "Hubbell, {Howard R.} and Vargas, {Hugo E} and Tsujimoto, {Karen L.} and Gibson, {George D.} and Pequignot, {Edward C.} and Bigler, {Robert D.} and Carter, {William A.} and Strayer, {David R.}",
year = "1992",
month = "5",
doi = "10.1007/BF01756181",
language = "English (US)",
volume = "35",
pages = "151--157",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft

AU - Hubbell, Howard R.

AU - Vargas, Hugo E

AU - Tsujimoto, Karen L.

AU - Gibson, George D.

AU - Pequignot, Edward C.

AU - Bigler, Robert D.

AU - Carter, William A.

AU - Strayer, David R.

PY - 1992/5

Y1 - 1992/5

N2 - The antitumor effects of recombinant interleukin-2 (rIL-2) and mismatched double-stranded RNA (dsRNA) were assessed in tissue culture and in a nude mouse model. Mismatched dsRNA did not show a direct antiproliferative effect against the human malignant melanoma cell line, BRO, in tissue culture. However, treatment of the BRO cells with up to 1000 units/ml rIL-2 in culture showed a slight increase in growth rate. Combined rIL-2/mismatched dsRNA treatment also demonstrated a similar slight enhancement of growth. Nude mice bearing subcutaneous tumors were treated by intraperitoneal injection of low doses (5000-20 000 units) of rIL-2 and mismatched dsRNA (500 μg). The in vivo tumor growth was significantly inhibited by the combined treatments (P <0.05) and survival was significantly increased (P <0.05). Measurement of cytotoxicity using splenocytes from treated animals showed significant augmentation of lytic activity against natural killer(NK)-sensitive YAC-1 cells in all rIL-2/mismatched dsRNA treatment groups, compared to the individual treatments or controls (P <0.05). Cytotoxicity of the splenocytes against the NK-resistant BRO cells was also augmented in animals treated with mismatched dsRNA and the highest rIL-2 dose utilized here (P <0.01). Renal, liver, and hematological toxicity was evaluated by measurement of blood urea nitrogen, creatinine, serum asparrtate aminotransferase, and a complete blood count with differential. There were no significant differences in these parameters in any of the treatment groups. Similarly, no differences in weight of the animals was seen in any treatment group. These results indicate that the combination of low-dose rIL-2 and mismatched dsRNA can potentiate host-mediated antitumor effects, yielding increased survival, without significant toxicity.

AB - The antitumor effects of recombinant interleukin-2 (rIL-2) and mismatched double-stranded RNA (dsRNA) were assessed in tissue culture and in a nude mouse model. Mismatched dsRNA did not show a direct antiproliferative effect against the human malignant melanoma cell line, BRO, in tissue culture. However, treatment of the BRO cells with up to 1000 units/ml rIL-2 in culture showed a slight increase in growth rate. Combined rIL-2/mismatched dsRNA treatment also demonstrated a similar slight enhancement of growth. Nude mice bearing subcutaneous tumors were treated by intraperitoneal injection of low doses (5000-20 000 units) of rIL-2 and mismatched dsRNA (500 μg). The in vivo tumor growth was significantly inhibited by the combined treatments (P <0.05) and survival was significantly increased (P <0.05). Measurement of cytotoxicity using splenocytes from treated animals showed significant augmentation of lytic activity against natural killer(NK)-sensitive YAC-1 cells in all rIL-2/mismatched dsRNA treatment groups, compared to the individual treatments or controls (P <0.05). Cytotoxicity of the splenocytes against the NK-resistant BRO cells was also augmented in animals treated with mismatched dsRNA and the highest rIL-2 dose utilized here (P <0.01). Renal, liver, and hematological toxicity was evaluated by measurement of blood urea nitrogen, creatinine, serum asparrtate aminotransferase, and a complete blood count with differential. There were no significant differences in these parameters in any of the treatment groups. Similarly, no differences in weight of the animals was seen in any treatment group. These results indicate that the combination of low-dose rIL-2 and mismatched dsRNA can potentiate host-mediated antitumor effects, yielding increased survival, without significant toxicity.

KW - Antitumor effects

KW - Human melanoma xenografts

KW - Interleukin-2

KW - Lymphokine-activated killer cells

KW - Mismatched dsRNA

UR - http://www.scopus.com/inward/record.url?scp=0026736146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026736146&partnerID=8YFLogxK

U2 - 10.1007/BF01756181

DO - 10.1007/BF01756181

M3 - Article

C2 - 1638550

AN - SCOPUS:0026736146

VL - 35

SP - 151

EP - 157

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -